BridgeMD
Immune-Related Rheumatological and neurological Adverse Events study.
EU CTIS ID: 2024-516631-27-00
What this study is testing
To characterize common and distinct immunological pathomechanisms in rheumatological and neurological immune-related adverse events (R- and N-irAEs) induced by checkpoint inhibitors (ICI) compared to immune-mediated inflammatory diseases (IMID’s). Co-primary objective: To collect and define data on diagnosis and management of rheumatological and neurological irAE’s in patients with cancer starting therapy with checkpoint inhibitors.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ≥18 yr.
- Diagnosed with any oncological disease with or without pre-existing auto-immune disease
- Starting with ICI therapy (ICI therapy defined as treatment with anti-PD1, anti-PDL1, anti-CTLA-4 or newly registered immune checkpoint therapies, either in mono- or combination therapy)
You likely can't join if
- Previous treatment with ICI therapy.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.